:: Library Catalog

Cover Image

Saved in:

Bibliographic Details
Main Authors:	Alba López‐Bravo, Ane Mínguez‐Olaondo, Candela Nieves‐Castellanos, Marta Ruibal‐Salgado, Noemí Morollón Sánchez‐Mateos, María Pilar Navarro‐Pérez, Alicia Alpuente, Marta Torres‐Ferrús, Jésica García‐Ull, Ana Gago‐Veiga, David García‐Azorín, Alicia González‐Martínez, Álvaro Sierra, Sonia Santos‐Lasaosa
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Headache: The Journal of Head and Face Pain
Online Access:	https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.14913
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine
by: Anna de Dios, et al.
Published: (2024)

Response to: Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked immunosorbent assays
by: Alicia Alpuente, et al.
Published: (2026)

Effectiveness and tolerability of galcanezumab for migraine prevention in patients ≥65 years: A real‐life multicenter study
by: Julia Peris‐Subiza, et al.
Published: (2025)

Evaluation of the effectiveness and safety of anti‐CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO ‐ CGRP study
by: María Clara García‐Castillo, et al.
Published: (2026)

Letter to the Editor regarding “Persistence, effectiveness, and tolerability of anti‐calcitonin gene‐related peptide monoclonal antibodies in patients with chronic migraine”
by: Joaquín Borrás‐Blasco, et al.
Published: (2025)

Differences in circulating alpha‐calcitonin gene–related peptide levels in inflammatory bowel disease and its relation to migraine comorbidity: A cross‐sectional study
by: Marta Pascual‐Mato, et al.
Published: (2024)

Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials
by: Jennifer Robblee, et al.
Published: (2024)

Genetic migraine disorders and the response to calcitonin gene‐related peptide antagonist treatment
by: Andrea M. Kuczynski, et al.
Published: (2025)

Evaluating dual calcitonin gene‐related peptide antagonists for chronic migraine prevention
by: Kara S. Graves, et al.
Published: (2026)

Long‐term evolution of white and gray matter structural properties in migraine
by: Álvaro Planchuelo‐Gómez, et al.
Published: (2025)

Patient reported outcomes and the real‐world use of calcitonin gene–related peptide medications in migraine
by: Samuel K. Peasah, et al.
Published: (2024)

Delayed urticaria during treatment with anti‐ CGRP monoclonal antibodies in migraine
by: Christoph T. Berger, et al.
Published: (2026)

Treatment of abdominal migraine in an 8‐year‐old child with calcitonin gene‐related peptide receptor antagonist: A case report
by: Yunzhu Tang, et al.
Published: (2025)

Effectiveness of switching strategies in CGRP monoclonal antibody therapy for migraine: A retrospective cohort study
by: Alex Jaimes, et al.
Published: (2024)

The pathogenic role of calcitonin gene‐related peptide and predictors of new‐onset migraine and long‐term outcomes after transcatheter atrial septal defect closure
by: Tzu‐Hsuan Su, et al.
Published: (2024)

Effects of fremanezumab on migraine‐associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial
by: Muneto Tatsumoto, et al.
Published: (2024)

Migraine, idiopathic intracranial hypertension, and calcitonin gene‐related peptide antibodies
by: Irina Krikova, et al.
Published: (2024)

Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open‐label ASCEND acute migraine study
by: Jessica Ailani, et al.
Published: (2025)

Serum levels of autotaxin reveal its role as a novel biomarker of migraine
by: Alberto Ouro, et al.
Published: (2025)

Mapping the migraine: Intracranial recording of cortical spreading depression in migraine with aura
by: Graham A. McLeod, et al.
Published: (2025)

Amplifying and ameliorating light avoidance in mice with photoreceptor targeting and calcitonin gene‐related peptide sensitization
by: Eric A. Kaiser, et al.
Published: (2025)

A critical appraisal of the International Classification of Headache Disorders migraine diagnostic criteria based on a retrospective multicenter cross‐sectional headache registry study in youth
by: Carlyn Patterson Gentile, et al.
Published: (2024)

The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine
by: Rikki Mangrum, et al.
Published: (2024)

The effect of different exercise types on migraine frequency in individuals with migraine: A pilot study
by: Yunus Emre Meydanal, et al.
Published: (2025)

Potential drug interaction between calcitonin gene‐related peptide antagonists and neonatal Fc receptor inhibitors
by: Alex Harlan, et al.
Published: (2025)

Arterial hypertension: A safety risk of calcitonin gene‐related peptide ligand and receptor blocker class
by: David Croteau, et al.
Published: (2026)

Evaluating associations of migraine‐related vertigo
by: Nazia Karsan, et al.
Published: (2025)

A phase 1, multicenter, open‐label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraine
by: Chay Ngee Lim, et al.
Published: (2025)

Afterimage duration differs for migraine with or without aura
by: Florian Rimmele, et al.
Published: (2025)

Mechanisms for mindfulness in migraine: Does catastrophizing matter?
by: Rebecca Erwin Wells, et al.
Published: (2024)

Useful considerations for treating migraine in patients with autism
by: Sinifunanya E. Nwaobi
Published: (2026)

Lifestyle triggers of migraine: Sleep restriction and caffeine lower the threshold for migraine‐like responses in rats in a sex‐specific manner
by: Gabriel Camargo de Oliveira, et al.
Published: (2026)

Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study
by: Shuu‐Jiun Wang, et al.
Published: (2024)

No association between migraine and HLA alleles in a cohort of 13,210 individuals with migraine from the Danish Blood Donor Study
by: Inga Zalia Tummoszeit, et al.
Published: (2024)

Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features
by: Chia‐Chun Chiang, et al.
Published: (2024)

Development and pharmacological characterization of novel multi‐ calcitonin gene‐related peptide and pituitary adenylate cyclase‐activating peptide receptor antagonists
by: Zoe Tasma, et al.
Published: (2025)

Counting the cost: How migraine shapes lives and economies
by: Risako Shirane, et al.
Published: (2025)

Cardiovascular risk and triptan usage among patients with migraine
by: Ido Peles, et al.
Published: (2025)

Depression and anxiety are not associated with migraine outcomes in children and adolescents
by: Amy A. Gelfand
Published: (2024)

Cognitive and emotional mechanisms underlying migraine quality of life
by: Shiri Shinan‐Altman, et al.
Published: (2026)